The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or ent1(-/-) mouse erythrocytes

Christopher J. Endres, Aaron M. Moss, Ban Ke, Rajgopal Govindarajan, Doo Sup Choi, Robert O. Messing, Jashvant D. Unadkat

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The polar nucleoside drug ribavirin is front-line treatment for chronic hepatitis C virus infection. The human equilibrative nucleoside transporter (ENT) 1 transports ribavirin into erythro- cytes where it is phosphorylated. These phosphorylated metabolites accumulate in the erythrocytes and produce dose- limiting hemolytic anemia. Here, we examined the in vitro and ex vivo transport and metabolism of ribavirin by erythrocytes isolated from humans and Ent1-null mice. Ribavirin (2.4 μM) uptake was significantly higher (1044 ± 255 amol/μg/10 s) into erythrocytes from Ent1(+/+) mice compared with that from Ent1(-/-) mice (76.48 ± 11.20 amol/pg/10 s). Our results showed a saturable (K m of 382 ± 75.1 μM) transport of [ 3H]riba-virin into erythrocytes from Ent1(+/+) mice. We found that ribavirin concentration rapidly (within 60 s) reached equilibrium in erythrocytes using a time course of [ 3H]ribavirin transport (2.5 μM) and metabolism in mouse and human erythrocytes for 8 h. However, total radioactivity of ribavirin was predominantly attributed to the phosphorylated metabolites ribavirin monophosphate and ribavirin triphosphate. Our findings allow us to estimate ribavirin transport, diffusion, and metabolic clearance and to predict in vivo accumulation of ribavirin phosphates in erythrocytes of both mice and humans. Our modeling of ribavirin in erythrocytes on long-term administration of ribavirin suggests that the accumulation of ribavirin inside the cells is dependent on ENT1/Ent1 transport and the rates of intracellular phosphorylation and the degradation of the phosphorylated metabolites. We predict that Ent1(+/+) and Ent1(-/-) mice will serve as excellent models to investigate the contribution of Ent1 to the pharmacokinetics and toxicity of ribavirin in vivo.

Original languageEnglish (US)
Pages (from-to)387-398
Number of pages12
JournalJournal of Pharmacology and Experimental Therapeutics
Volume329
Issue number1
DOIs
StatePublished - Apr 2009

Fingerprint

Equilibrative Nucleoside Transporter 1
Ribavirin
Erythrocytes

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or ent1(-/-) mouse erythrocytes. / Endres, Christopher J.; Moss, Aaron M.; Ke, Ban; Govindarajan, Rajgopal; Choi, Doo Sup; Messing, Robert O.; Unadkat, Jashvant D.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 329, No. 1, 04.2009, p. 387-398.

Research output: Contribution to journalArticle

Endres, Christopher J. ; Moss, Aaron M. ; Ke, Ban ; Govindarajan, Rajgopal ; Choi, Doo Sup ; Messing, Robert O. ; Unadkat, Jashvant D. / The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or ent1(-/-) mouse erythrocytes. In: Journal of Pharmacology and Experimental Therapeutics. 2009 ; Vol. 329, No. 1. pp. 387-398.
@article{4b462a98447f4725ba291f01cb27d798,
title = "The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or ent1(-/-) mouse erythrocytes",
abstract = "The polar nucleoside drug ribavirin is front-line treatment for chronic hepatitis C virus infection. The human equilibrative nucleoside transporter (ENT) 1 transports ribavirin into erythro- cytes where it is phosphorylated. These phosphorylated metabolites accumulate in the erythrocytes and produce dose- limiting hemolytic anemia. Here, we examined the in vitro and ex vivo transport and metabolism of ribavirin by erythrocytes isolated from humans and Ent1-null mice. Ribavirin (2.4 μM) uptake was significantly higher (1044 ± 255 amol/μg/10 s) into erythrocytes from Ent1(+/+) mice compared with that from Ent1(-/-) mice (76.48 ± 11.20 amol/pg/10 s). Our results showed a saturable (K m of 382 ± 75.1 μM) transport of [ 3H]riba-virin into erythrocytes from Ent1(+/+) mice. We found that ribavirin concentration rapidly (within 60 s) reached equilibrium in erythrocytes using a time course of [ 3H]ribavirin transport (2.5 μM) and metabolism in mouse and human erythrocytes for 8 h. However, total radioactivity of ribavirin was predominantly attributed to the phosphorylated metabolites ribavirin monophosphate and ribavirin triphosphate. Our findings allow us to estimate ribavirin transport, diffusion, and metabolic clearance and to predict in vivo accumulation of ribavirin phosphates in erythrocytes of both mice and humans. Our modeling of ribavirin in erythrocytes on long-term administration of ribavirin suggests that the accumulation of ribavirin inside the cells is dependent on ENT1/Ent1 transport and the rates of intracellular phosphorylation and the degradation of the phosphorylated metabolites. We predict that Ent1(+/+) and Ent1(-/-) mice will serve as excellent models to investigate the contribution of Ent1 to the pharmacokinetics and toxicity of ribavirin in vivo.",
author = "Endres, {Christopher J.} and Moss, {Aaron M.} and Ban Ke and Rajgopal Govindarajan and Choi, {Doo Sup} and Messing, {Robert O.} and Unadkat, {Jashvant D.}",
year = "2009",
month = "4",
doi = "10.1124/jpet.108.145854",
language = "English (US)",
volume = "329",
pages = "387--398",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - The role of the equilibrative nucleoside transporter 1 (ENT1) in transport and metabolism of ribavirin by human and wild-type or ent1(-/-) mouse erythrocytes

AU - Endres, Christopher J.

AU - Moss, Aaron M.

AU - Ke, Ban

AU - Govindarajan, Rajgopal

AU - Choi, Doo Sup

AU - Messing, Robert O.

AU - Unadkat, Jashvant D.

PY - 2009/4

Y1 - 2009/4

N2 - The polar nucleoside drug ribavirin is front-line treatment for chronic hepatitis C virus infection. The human equilibrative nucleoside transporter (ENT) 1 transports ribavirin into erythro- cytes where it is phosphorylated. These phosphorylated metabolites accumulate in the erythrocytes and produce dose- limiting hemolytic anemia. Here, we examined the in vitro and ex vivo transport and metabolism of ribavirin by erythrocytes isolated from humans and Ent1-null mice. Ribavirin (2.4 μM) uptake was significantly higher (1044 ± 255 amol/μg/10 s) into erythrocytes from Ent1(+/+) mice compared with that from Ent1(-/-) mice (76.48 ± 11.20 amol/pg/10 s). Our results showed a saturable (K m of 382 ± 75.1 μM) transport of [ 3H]riba-virin into erythrocytes from Ent1(+/+) mice. We found that ribavirin concentration rapidly (within 60 s) reached equilibrium in erythrocytes using a time course of [ 3H]ribavirin transport (2.5 μM) and metabolism in mouse and human erythrocytes for 8 h. However, total radioactivity of ribavirin was predominantly attributed to the phosphorylated metabolites ribavirin monophosphate and ribavirin triphosphate. Our findings allow us to estimate ribavirin transport, diffusion, and metabolic clearance and to predict in vivo accumulation of ribavirin phosphates in erythrocytes of both mice and humans. Our modeling of ribavirin in erythrocytes on long-term administration of ribavirin suggests that the accumulation of ribavirin inside the cells is dependent on ENT1/Ent1 transport and the rates of intracellular phosphorylation and the degradation of the phosphorylated metabolites. We predict that Ent1(+/+) and Ent1(-/-) mice will serve as excellent models to investigate the contribution of Ent1 to the pharmacokinetics and toxicity of ribavirin in vivo.

AB - The polar nucleoside drug ribavirin is front-line treatment for chronic hepatitis C virus infection. The human equilibrative nucleoside transporter (ENT) 1 transports ribavirin into erythro- cytes where it is phosphorylated. These phosphorylated metabolites accumulate in the erythrocytes and produce dose- limiting hemolytic anemia. Here, we examined the in vitro and ex vivo transport and metabolism of ribavirin by erythrocytes isolated from humans and Ent1-null mice. Ribavirin (2.4 μM) uptake was significantly higher (1044 ± 255 amol/μg/10 s) into erythrocytes from Ent1(+/+) mice compared with that from Ent1(-/-) mice (76.48 ± 11.20 amol/pg/10 s). Our results showed a saturable (K m of 382 ± 75.1 μM) transport of [ 3H]riba-virin into erythrocytes from Ent1(+/+) mice. We found that ribavirin concentration rapidly (within 60 s) reached equilibrium in erythrocytes using a time course of [ 3H]ribavirin transport (2.5 μM) and metabolism in mouse and human erythrocytes for 8 h. However, total radioactivity of ribavirin was predominantly attributed to the phosphorylated metabolites ribavirin monophosphate and ribavirin triphosphate. Our findings allow us to estimate ribavirin transport, diffusion, and metabolic clearance and to predict in vivo accumulation of ribavirin phosphates in erythrocytes of both mice and humans. Our modeling of ribavirin in erythrocytes on long-term administration of ribavirin suggests that the accumulation of ribavirin inside the cells is dependent on ENT1/Ent1 transport and the rates of intracellular phosphorylation and the degradation of the phosphorylated metabolites. We predict that Ent1(+/+) and Ent1(-/-) mice will serve as excellent models to investigate the contribution of Ent1 to the pharmacokinetics and toxicity of ribavirin in vivo.

UR - http://www.scopus.com/inward/record.url?scp=64049096186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64049096186&partnerID=8YFLogxK

U2 - 10.1124/jpet.108.145854

DO - 10.1124/jpet.108.145854

M3 - Article

C2 - 19164463

AN - SCOPUS:64049096186

VL - 329

SP - 387

EP - 398

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -